Submit to Current Oncology Review for Current Oncology Propose a Special Issue

Journal Menu

Journal Browser

Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment

Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Bone and Soft Tissue Oncology".

Deadline for manuscript submissions: closed (15 August 2023) | Viewed by 34141

Share This Special Issue

Special Issue Editors

Dr. Andrea Sambri

E-Mail Website
Guest Editor

Orthopaedics and Traumatology Unit, IRRCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
Interests: bone infections; prosthetic infections; megaprosthesis; orthopaedics; musculoskeletal infections; musculoskeletal tumours
Special Issues, Collections and Topics in MDPI journals

Dr. Michele Fiore

E-Mail Website
Guest Editor

Orthopaedics and Traumatology Unit, IRRCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
Interests: orthopaedics; traumatology; custom-made bone reconstruction; muscoloskeletal infections; bone and soft-tissue sarcomas; spine surgery
Special Issues, Collections and Topics in MDPI journals

Dr. Massimiliano De Paolis

E-Mail Website
Guest Editor

Orthopaedics and Traumatology Unit—IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
Interests: orthopaedics; traumatology; custom-made bone reconstruction; muscoloskeletal infections; bone and soft-tissue sarcomas
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bone and soft-tissue tumours are relatively rare tumours in both children and adults, with over 100 different histologic subtypes. Concerning muscoloskeletal malignancies, a further complication in the clinical issues related to the low-incidence pathologies is their variable presentation, behaviour, and long-term outcomes. However, in recent decades, the results of basic research and the testing of new knowledge through cooperative clinical trials has led to the achievement of a remarkable improvement in prognosis. Nevertheless, the rarity and variety of these diseases hinders this process. Therefore, we consider frequent updates on the new evidence regarding this issue to be essential.

This Special Issue, “Updates in bone and soft tissue tumours“, aims to collect data and experiences from clinical and pre-clinical activities arising from the management of patients with muscoloskeletal malignancies.

We are pleased to invite you to participate in the production of this Special Issue. We strongly believe that only the increased dissemination of knowledge can contribute to the optimisation of the management of such complex matters. In this Special Issue, both original research articles and reviews are welcome. Research areas may include, but are not limited to, the following:

Genetic and epigenetic findings;
Pathology and immunochemistry;
Imaging;
Clinical presentations;
Oncologic treatments;
Orthopaedic surgical management.

We look forward to receiving your contributions.

Dr. Andrea Sambri
Dr. Michele Fiore
Dr. Massimiliano De Paolis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

bone tumours
soft-tissue tumours
sarcoma
upper and lower extremities
spine
oncology
oncological orthopaedics
ortho-paedic reconstructions

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (9 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

9 pages, 770 KiB

Open AccessArticle

Multidisciplinary Treatment of Merkel Cell Carcinoma of the Extremities: Outcomes and Factors Associated with Poor Survival in Nodal Disease

by Samuel E. Broida, Xiao T. Chen, Brian D. Wahlig, Steven L. Moran and Matthew T. Houdek

Curr. Oncol. 2023, 30(7), 6246-6254; https://doi.org/10.3390/curroncol30070462 - 30 Jun 2023

Cited by 3 | Viewed by 1614

Abstract

Merkel cell carcinoma (MCC) has a tendency for lymphatic spread and locoregional recurrence, although there is little data examining the risk factors for patients with lymph node-positive extremity lesions. The purpose of the current study was to examine the outcomes and risk factors associated with nodal metastasis in extremity MCC. We retrospectively reviewed the medical record of 120 patients with extremity MCC evaluated at our institution between 1994 and 2021. The mean age of this cohort was 71 years; 33% of patients were female; and 98% were Caucasian. Seventy-eight (65%) patients presented with localized disease. Thirty-seven (31%) patients had stage III disease, and five (4%) patients had stage IV disease. Treatment of primary lesions consisted primarily of margin-negative excision and adjuvant radiotherapy. Nodal metastases were most treated with adjuvant radiation or completion lymph node dissection. Five-year disease-specific survival in our series was 88% for patients with localized disease, 89% for stage IIIa disease, 40% for stage IIIb disease and 42% for stage IV. Factors associated with worse survival included immunosuppression and macroscopic nodal disease. In conclusion, extremity MCC has a low rate of local recurrence when treated with margin-negative excision and adjuvant radiation. However, treatment of nodal metastases remains a challenge with high rates of recurrence and mortality, particularly for patients who are immunosuppressed or who have macroscopic nodal disease. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Graphical abstract

16 pages, 2128 KiB

Open AccessArticle

Association between Inflammatory Markers and Local Recurrence in Patients with Giant Cell Tumor of Bone: A Preliminary Result

by Shinji Tsukamoto, Andreas F. Mavrogenis, Rebeca Angulo Alvarado, Matteo Traversari, Manabu Akahane, Kanya Honoki, Yasuhito Tanaka, Davide Maria Donati and Costantino Errani

Curr. Oncol. 2023, 30(1), 1116-1131; https://doi.org/10.3390/curroncol30010085 - 13 Jan 2023

Cited by 2 | Viewed by 2687

Abstract

Giant cell tumor of bone (GCTB) has a high local recurrence rate of approximately 20%. Systemic inflammatory markers, such as neutrophil-lymphocyte ratio (NLR), modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), hemoglobin (Hb), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH), have been reported as prognostic markers in patients with malignant tumors. This study aimed to investigate the correlation between these markers and the local recurrence rate of GCTB. In total, 103 patients with GCTB who underwent surgery at the authors’ institutions between 1993 and 2021 were included. Thirty patients experienced local recurrence. Univariate and multivariate analysis showed that tumor site, preoperative and postoperative denosumab treatment, and surgery were significantly associated with local recurrence-free survival. LDH was associated with local recurrence-free survival on univariate analysis only. NLR, mGPS, PNI, LMR, and PLR score did not correlate with the local recurrence rate. In conclusion, NLR, mGPS, PNI, LMR, PLR score, Hb, ALP, and LDH levels are not correlated with the local recurrence rate of GCTB. However, due to the small number of patients included in this study, this result should be re-evaluated in a multicenter study with a larger sample size. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Figure 1

10 pages, 563 KiB

Open AccessArticle

A Planned Multidisciplinary Surgical Approach to Treat Primary Pelvic Malignancies

by Andrea Sambri, Michele Fiore, Matteo Rottoli, Giuseppe Bianchi, Marco Pignatti, Marta Bortoli, Amelio Ercolino, Stefano Ancetti, Anna Myriam Perrone, Pierandrea De Iaco, Riccardo Cipriani, Eugenio Brunocilla, Davide Maria Donati, Mauro Gargiulo, Gilberto Poggioli and Massimiliano De Paolis

Curr. Oncol. 2023, 30(1), 1106-1115; https://doi.org/10.3390/curroncol30010084 - 12 Jan 2023

Cited by 3 | Viewed by 2226

Abstract

The pelvic anatomy poses great challenges to orthopedic surgeons. Sarcomas are often large in size and typically enclosed in the narrow confines of the pelvis with the close proximity of vital structures. The aim of this study is to report a systematic planned multidisciplinary surgical approach to treat pelvic sarcomas. Seventeen patients affected by bone and soft tissue sarcomas of the pelvis, treated using a planned multidisciplinary surgical approach, combining the expertise of orthopedic oncology and other surgeons (colleagues from urology, vascular surgery, abdominal surgery, gynecology and plastic surgery), were included. Seven patients were treated with hindquarter amputation; 10 patients underwent excision of the tumor. Reconstruction of bone defects was conducted in six patients with a custom-made 3D-printed pelvic prosthesis. Thirteen patients experienced at least one complication. Well-organized multidisciplinary collaborations between each subspecialty are the cornerstone for the management of patients affected by pelvic sarcomas, which should be conducted in specialized centers. A multidisciplinary surgical approach is of paramount importance in order to obtain the best successful surgical results and adequate margins for achieving acceptable outcomes. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Figure 1

7 pages, 2673 KiB

Open AccessCommunication

Thin Cartilage Cap May Be Related to the Spontaneous Regression in Pediatric Patients with Osteochondroma

by Ryohei Adachi, Tomoki Nakamura, Kunihiro Asanuma, Tomohito Hagi, Teruya Uchiyama and Akihiro Sudo

Curr. Oncol. 2022, 29(12), 9884-9890; https://doi.org/10.3390/curroncol29120777 - 15 Dec 2022

Viewed by 2456

Abstract

Background: The spontaneous regression of osteochondromas is rare, and only a few cases have been reported. Furthermore, the precise mechanism underlying spontaneous regression is unknown. This study aimed to examine the radiological findings of osteochondromas that had spontaneous regression and to identify potential indicators of this uncommon phenomenon in skeletally immature patients with osteochondromas. Methods: We included 28 patients (15 males and 13 females) who met the eligibility criteria between 2002 and 2019. The mean age at initial diagnosis was 9.7 years old (2–16 years). The mean follow-up period was 6.4 years (3–16 years). Results: Of the 28 patients, 10 (35.7%) had osteochondroma resolution. The osteochondroma resolved in one patient and regressed in nine. Tumor shrinkage is related to the thickness of the cartilage cap. The thickness of the cartilage cap did not correlate with age. Conclusions: Tumor shrinkage is associated with a thinner cartilage cap on magnetic resonance imaging. The thickness of the cartilage cap may be an important predictor of spontaneous regression in pediatric patients with osteochondroma. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Figure 1

17 pages, 3936 KiB

Open AccessArticle

Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone

by Mengke Fan, Guochuan Zhang, Mingfang Xie, Xinbo Liu, Qi Zhang and Ling Wang

Curr. Oncol. 2022, 29(10), 7655-7671; https://doi.org/10.3390/curroncol29100605 - 13 Oct 2022

Cited by 9 | Viewed by 2984

Abstract

The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients. Although the treatment methods for a GCTB, such as scraping and resection, effectively inhibit the disease, the tendency toward malignant transformation remains. Therefore, it is important to identify new treatment methods for a GCTB. In this study, we first found high Siglec-15 expression in GCTB tissues, which was significantly associated with Campanacci staging and tumor recurrence. In Spearman’s analysis, Siglec-15 expression was significantly correlated with Ki-67 levels in tumor tissues. In vitro, the mRNA and protein levels of Siglec-15 were high in GCTB stromal cells (Hs737. T), and Siglec-15 knockdown inhibited the biological characteristics of GCTB stromal cells. The RNA sequencing results enabled a prediction of the downstream genes by using the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and MCODE analyses, and the findings showed that CXCL8 was significantly regulated by Siglec-15 and might be a promising downstream target gene of Siglec-15. Therefore, Siglec-15 may be a potential immunotherapy target for a GCTB. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Figure 1

Review

Jump to: Research

11 pages, 1084 KiB

Open AccessReview

Phosphaturic Mesenchymal Tumors with or without Phosphate Metabolism Derangements

by Andrea Montanari, Maria Giulia Pirini, Ludovica Lotrecchiano, Lorenzo Di Prinzio and Guido Zavatta

Curr. Oncol. 2023, 30(8), 7478-7488; https://doi.org/10.3390/curroncol30080541 - 8 Aug 2023

Cited by 11 | Viewed by 2967

Abstract

Phosphaturic mesenchymal tumors (PMT) are rare neoplasms, which can give rise to a multifaceted syndrome, otherwise called tumor-induced osteomalacia (TIO). Localizing these tumors is crucial to obtain a cure for the phosphate metabolism derangement, which is often the main cause leading the patient to seek medical help, because of invalidating physical and neuromuscular symptoms. A proportion of these tumors is completely silent and may grow unnoticed, unless they become large enough to produce pain or discomfort. FGF-23 can be produced by several benign or malignant PMTs. The phosphate metabolism, radiology and histology of these rare tumors must be collectively assessed by a multidisciplinary team aimed at curing the disease locally and improving patients’ quality of life. This narrative review, authored by multiple specialists of a tertiary care hospital center, will describe endocrine, radiological and histological features of these tumors, as well as present surgical and interventional strategies to manage PMTs. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Figure 1

18 pages, 522 KiB

Open AccessReview

Chemotherapy Regimens for Non-Metastatic Conventional Appendicular Osteosarcoma: A Literature Review Based on the Outcomes

by Joaquim Soares do Brito, Rodrigo Santos, Marco Sarmento, Pedro Fernandes and José Portela

Curr. Oncol. 2023, 30(7), 6148-6165; https://doi.org/10.3390/curroncol30070457 - 27 Jun 2023

Cited by 4 | Viewed by 2673

Abstract

Osteosarcoma is a rare condition with a complex treatment. Most protocols include neoadjuvant chemotherapy, surgery, and consolidation chemotherapy as the standard of treatment. However, the use of neoadjuvant chemotherapy lacks scientific evidence proving superiority in opposition to the use of isolated chemotherapy in an adjuvant regimen after surgery. We conducted a review for studies published in English between 1980 and 2020, using the MEDLINE/PubMed and Scopus electronic databases, to evaluate the outcomes when using neoadjuvant chemotherapy or adjuvant chemotherapy strategies in the treatment of non-metastatic appendicular osteosarcoma, as well as the toxicity associated with different chemotherapeutic regimens. Patients were divided into a neoadjuvant chemotherapy group (NAC) and adjuvant chemotherapy group (ACT), depending on the chemotherapy regimen used in association with surgery. A total of 1254 articles in English were screened by title and abstract, and 146 were pre-selected for full reading and analysis. A total of 24 assays matching the inclusion criteria were selected: 10 prospective and 14 retrospective studies. This review points to an absence of significative differences in outcomes, namely overall survival, disease-free survival/event-free survival rates, or toxicity, regarding neoadjuvant or single adjuvant chemotherapy strategies used in the treatment of appendicular non-metastatic osteosarcomas. However, there is a significative difference in population dimensions between the NAC and the ACT groups. Additionally, clinical presentation, tumor localization, tumor volume, or histological type were not considered, with these variables presenting the potential to influence these results. Despite these limitations, our findings should allow a re-thinking of our current practice and promote new opportunities to optimize treatment, always looking towards better survival and lower complications rates. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Figure 1

12 pages, 1215 KiB

Open AccessReview

Current Concepts in the Resection of Bone Tumors Using a Patient-Specific Three-Dimensional Printed Cutting Guide

by Hisaki Aiba, Benedetta Spazzoli, Shinji Tsukamoto, Andreas F. Mavrogenis, Tomas Hermann, Hiroaki Kimura, Hideki Murakami, Davide Maria Donati and Costantino Errani

Curr. Oncol. 2023, 30(4), 3859-3870; https://doi.org/10.3390/curroncol30040292 - 29 Mar 2023

Cited by 10 | Viewed by 3614

Abstract

Orthopedic oncology has begun to use three-dimensional-printing technology, which is expected to improve the accuracy of osteotomies, ensure a safe margin, and facilitate precise surgery. However, several difficulties should be considered. Cadaver and clinical studies have reported more accurate osteotomies for bone-tumor resection using patient-specific cutting guides, especially in challenging areas such as the sacrum and pelvis, compared to manual osteotomies. Patient-specific cutting guides can help surgeons achieve resection with negative margins and reduce blood loss and operating time. Furthermore, this patient-specific cutting guide could be combined with more precise reconstruction using patient-specific implants or massive bone allografts. This review provides an overview of the basic technologies used in the production of patient-specific cutting guides and discusses their current status, advantages, and limitations. Moreover, we summarize cadaveric and clinical studies on the use of these guides in orthopedic oncology. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Figure 1

17 pages, 4574 KiB

Open AccessReview

Soft Tissue Masses of the Hand: A Review of Clinical Presentation and Imaging Features

by Samuel AbuMoussa, Mona Pari Roshan, Felipe Ferreira Souza, Dane Daley, Andrew Rosenberg, Juan Pretell, Natalia Fullerton and Ty Subhawong

Curr. Oncol. 2023, 30(2), 2032-2048; https://doi.org/10.3390/curroncol30020158 - 7 Feb 2023

Cited by 8 | Viewed by 10956

Abstract

More than 15% of all soft-tissue tumors arise in the hand. Because of the location of these tumors, even small abnormalities may be alarming to patients on presentation. Although the majority of lesions are benign and can be diagnosed solely by history and physical examination, additional imaging workup may be required to confirm a diagnosis or define anatomic extent of involvement. This paper aims to review the basic epidemiology, clinical presentation, imaging findings, and treatment options of the more common soft-tissue tumors of the hand. Full article

(This article belongs to the Special Issue Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment)

► Show Figures

Journal Menu

Journal Browser

Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (9 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI